{"id":"hyperrab","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"f82880b8-998c-4659-8f20-6dcc81f258e9","title":"HYPERRAB (RABIES IMMUNE GLOBULIN (HUMAN)) INJECTION, SOLUTION [GRIFOLS USA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HyperRAB contains human rabies antibodies that neutralize rabies virus and prevent its spread to the central nervous system. It is administered as part of post-exposure prophylaxis (PEP) following potential rabies exposure, working in conjunction with rabies vaccine to provide immediate protection while the immune system develops active immunity.","oneSentence":"HyperRAB is a rabies immunoglobulin (human) that provides passive immunity by supplying antibodies against rabies virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:34:32.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-exposure prophylaxis of rabies in non-immunized individuals following potential rabies exposure"}]},"trialDetails":[{"nctId":"NCT07445815","phase":"PHASE2","title":"A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody","status":"NOT_YET_RECRUITING","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","startDate":"2026-01-31","conditions":"Rabies (Healthy Volunteers)","enrollment":200},{"nctId":"NCT07399951","phase":"EARLY_PHASE1","title":"Washington University WU 409: Immune Responses to Rabies Vaccine.","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2023-07-18","conditions":"Healthy Participants","enrollment":30},{"nctId":"NCT03961555","phase":"PHASE2","title":"Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2019-09-03","conditions":"Rabies","enrollment":448},{"nctId":"NCT07342257","phase":"PHASE1","title":"SYN023 With Rabies Vaccine in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2024-11-30","conditions":"Rabies Post-exposure Prophylaxis","enrollment":108},{"nctId":"NCT05382650","phase":"","title":"Survey of Human Rabies Immune Globulin Safety in Children","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-02-22","conditions":"Rabies, Rabies Human, Rabies Virus Infection","enrollment":35},{"nctId":"NCT04478084","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-04","conditions":"Rabies (Healthy Volunteers)","enrollment":403},{"nctId":"NCT04594551","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-11","conditions":"Rabies (Healthy Volunteers)","enrollment":201},{"nctId":"NCT03965962","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-07-01","conditions":"Rabies (Healthy Volunteers)","enrollment":640},{"nctId":"NCT05846568","phase":"PHASE3","title":"Study to Evaluate GR1801's Efficacy and Safety","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2022-10-21","conditions":"Rabies Post-exposure Prophylaxis","enrollment":1200},{"nctId":"NCT04644484","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2020-09-23","conditions":"Rabies, Communicable Disease, Virus Diseases","enrollment":1000},{"nctId":"NCT03524417","phase":"NA","title":"Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response","status":"UNKNOWN","sponsor":"Queen Saovabha Memorial Institute","startDate":"2018-04-30","conditions":"Rabies","enrollment":20},{"nctId":"NCT03145766","phase":"PHASE2","title":"Immunogenicity and Safety of a Purified Vero Rabies Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-04-17","conditions":"Rabies Virus","enrollment":320},{"nctId":"NCT02040090","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Kamada, Ltd.","startDate":"2013-04","conditions":"Rabies","enrollment":118},{"nctId":"NCT04213950","phase":"NA","title":"Improving Adherence to Rabies PEP Guideline Recommendations","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2019-12-29","conditions":"Rabies, Rabies Human, Rabies Virus Infection","enrollment":70},{"nctId":"NCT03264157","phase":"PHASE2, PHASE3","title":"Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Bio Products Laboratory","startDate":"2017-12-08","conditions":"Healthy","enrollment":162},{"nctId":"NCT02956746","phase":"PHASE1, PHASE2","title":"A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2016-08","conditions":"Human Rabies","enrollment":164},{"nctId":"NCT01610362","phase":"NA","title":"Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2012-06","conditions":"Rabies","enrollment":50},{"nctId":"NCT01641315","phase":"NA","title":"Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2015-09","conditions":"Rabies","enrollment":75},{"nctId":"NCT01137045","phase":"PHASE4","title":"Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2010-06","conditions":"Rabies","enrollment":210},{"nctId":"NCT02177032","phase":"PHASE3","title":"Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age","status":"COMPLETED","sponsor":"Novartis","startDate":"2014-06","conditions":"Rabies Infection","enrollment":885},{"nctId":"NCT03093545","phase":"NA","title":"Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-03","conditions":"Rabies","enrollment":60},{"nctId":"NCT02559921","phase":"PHASE2","title":"Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.","status":"COMPLETED","sponsor":"Beijing Chaoyang District Centre for Disease Control and Prevention","startDate":"2014-12","conditions":"Rabies","enrollment":300},{"nctId":"NCT01063140","phase":"","title":"Rabies Immune Plasma Booster Study","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2009-01","conditions":"Rabies","enrollment":491},{"nctId":"NCT02339896","phase":"","title":"Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children","status":"UNKNOWN","sponsor":"Queen Saovabha Memorial Institute","startDate":"2014-02","conditions":"Dog Bite","enrollment":45},{"nctId":"NCT02139657","phase":"PHASE1","title":"An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2014-03","conditions":"Rabies","enrollment":12},{"nctId":"NCT01228383","phase":"PHASE2","title":"Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-12","conditions":"Rabies","enrollment":240},{"nctId":"NCT00708084","phase":"PHASE2","title":"Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2008-05","conditions":"Rabies","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HRIG"],"phase":"marketed","status":"active","brandName":"HyperRAB","genericName":"HyperRAB","companyName":"Bio Products Laboratory","companyId":"bio-products-laboratory","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HyperRAB is a rabies immunoglobulin (human) that provides passive immunity by supplying antibodies against rabies virus. Used for Post-exposure prophylaxis of rabies in non-immunized individuals following potential rabies exposure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}